<b>Full Title</b><br> Protocol STML-ELA-0222: A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer <br><br> <b>Study Treatment</b><br> <u>Arm A</u>: Elacestrant + Alpelisib<br> <u>Arm B</u>: Elacestrant + Everolimus<br> <u>Arm C</u>: Elacestrant + Palbociclib<br> <u>Arm D</u>: Elacestrant + Ribociclib <br><br> <b>Eligibility/Info</b><br> Eligible patients will have ER+, HER2- metastatic breast cancer that has not been treated with chemotherapy in the metastatic setting but that has progressed after up to 2 prior lines of hormonal therapy that included a CDK4/6 inhibitor. Patients in arm A (alpelisib combination arm) must also have a documented PIK3CA mutation. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br>